6m5y: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Structure of human galectin-1 tandem-repeat mutant with lactose== | ==Structure of human galectin-1 tandem-repeat mutant with lactose== | ||
<StructureSection load='6m5y' size='340' side='right'caption='[[6m5y]]' scene=''> | <StructureSection load='6m5y' size='340' side='right'caption='[[6m5y]], [[Resolution|resolution]] 1.38Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6M5Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6M5Y FirstGlance]. <br> | <table><tr><td colspan='2'>[[6m5y]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6M5Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6M5Y FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6m5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6m5y OCA], [https://pdbe.org/6m5y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6m5y RCSB], [https://www.ebi.ac.uk/pdbsum/6m5y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6m5y ProSAT]</span></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BGC:BETA-D-GLUCOSE'>BGC</scene>, <scene name='pdbligand=GLC:ALPHA-D-GLUCOSE'>GLC</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene></td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">LGALS1 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6m5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6m5y OCA], [https://pdbe.org/6m5y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6m5y RCSB], [https://www.ebi.ac.uk/pdbsum/6m5y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6m5y ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | |||
[[https://www.uniprot.org/uniprot/LEG1_HUMAN LEG1_HUMAN]] May regulate apoptosis, cell proliferation and cell differentiation. Binds beta-galactoside and a wide array of complex carbohydrates. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase.<ref>PMID:14617626</ref> <ref>PMID:18796645</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Modification of the domain architecture of galectins has been attempted to analyze their biological functions and to develop medical applications. Several types of galectin-1 repeat mutants were previously reported but, however, it was not clear whether the native structure of the wild type was retained. In this study, we determined the crystal structure of a galectin-1 tandem-repeat mutant with a short linker peptide, and compared the unfolding profiles of the wild type and mutant by chemical denaturation. The structure of the mutant was consistent with that of the dimer of the wild type, and both carbohydrate-binding sites were retained. The unfolding curve of the wild type with lactose suggested that the dimer dissociation and the tertiary structure unfolding was concomitant at micromolar protein concentrations. The midpoint denaturant concentration of the wild type was dependent on the protein concentration and lower than that of the mutant. Linking the two subunits significantly stabilized the tertiary structure. The mutant exhibited higher T-cell growth-inhibition activity and comparable hemagglutinating activity. Structural stabilization may prevent the oxidation of the internal cysteine residue. | |||
Crystal structure and conformational stability of a galectin-1 tandem-repeat mutant with a short linker.,Nonaka Y, Ogawa T, Shoji H, Nishi N, Kamitori S, Nakamura T Glycobiology. 2021 Oct 27. pii: 6411845. doi: 10.1093/glycob/cwab101. PMID:34735570<ref>PMID:34735570</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 6m5y" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Galectin 3D structures|Galectin 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Kamitori S]] | [[Category: Kamitori, S]] | ||
[[Category: Nakamura T]] | [[Category: Nakamura, T]] | ||
[[Category: Nonaka Y]] | [[Category: Nonaka, Y]] | ||
[[Category: Apoptosis]] | |||
[[Category: Beta-sandwich]] | |||
[[Category: Immune regulation]] | |||
[[Category: Lectin]] | |||
[[Category: Sugar binding protein]] | |||